Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1998 Jan;8(1):79-100.
doi: 10.1111/j.1750-3639.1998.tb00138.x.

Recent advances in the biochemistry of sphingolipidoses

Affiliations
Review

Recent advances in the biochemistry of sphingolipidoses

T Kolter et al. Brain Pathol. 1998 Jan.

Abstract

Glycosphingolipids are ubiquitous membrane components of eukaryotic cells. They participate in various cell recognition events and can regulate enzymes and receptors within the plasma membrane. Sphingolipidoses are due to an impaired lysosomal digestion of these substances. Glycosphingolipids are degraded by the action of exohydrolases, which are supported, in the case of glycosphingolipids with short oligosaccharide chains, by sphingolipid activator proteins. Five sphingolipid activator proteins are known so far, the GM2-activator and the SAPs, SAP-A to D (also called saposins). Degradation of glycosphingolipids requires endocytic membrane flow of plasma membrane derived glycosphingolipids into the lysosomes. Recent research focused on the topology of this process and on the mechanism and physiological function of sphingolipid activator proteins. Limited knowledge is available about enzymology and topology of glycosphingolipid biosynthesis. Recently, intermediates of this metabolic pathway have been identified as novel signalling molecules. Inhibition of glycosphingolipid biosynthesis has been shown to be beneficial in the animal model of Tay-Sachs disease. Mice with disrupted genes for lysosomal hydrolases and activator proteins are useful models for known human diseases and are valuable tools for the study of glycosphingolipid metabolism, the pathogenesis of sphingolipidoses and novel therapeutic approaches.

PubMed Disclaimer

References

    1. Ballabio A, Shapiro LJ (1995) Steroid sulfatase deficiency and X‐linked ichthyosis. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver C, Beaudet AL, Sly WS, Valle D, (eds.), 7th Edition, Chapter 96, pp. 2999–3022, McGraw‐Hill: New York .
    1. Barton NW, Furrish FS, Murray GJ, Garfield M, Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 87: 1913–1916. - PMC - PubMed
    1. Bernardo K, Hurwitz R, Zenk T, Desnick RJ, Ferlinz K, Schuchman EH, Sandhoff K (1995) Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem 270: 11098–11102. - PubMed
    1. Bielawska A, Crane HM, Liotta D, Obeid LM, Hannun YA (1993) Selectivity of ceramide‐mediated biology ‐ lack of activity of erythro‐dihydroceramide. J Biol Chem 268: 26226–26232. - PubMed
    1. Bradova V, Smid F, Ulrich‐Bott B, Roggendorf W, Paton BC, Harzer K (1993) Prosaposin deficiency: further characterization of the sphingolipid activator protein‐deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease. Hum Genet 92: 143–152. - PubMed

LinkOut - more resources